Maravai LifeSciences/$MRVI
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Maravai LifeSciences
Maravai LifeSciences Holdings Inc is a life sciences company that provides critical products that drive the development of groundbreaking vaccines, drug therapies, cell and gene therapies, and diagnostics. The group's solutions empower research into human diseases and support the entire biopharmaceutical development process from early discovery to commercialization. Its reportable segments are Nucleic acid production and biologics safety testing. It generates a majority of its revenue from Nucleic Acid Production and focuses on the manufacturing and sale of nucleic acid products to support the needs of customers' research, and therapeutic and vaccine programs. In addition, the segment also provides research products for labeling and detecting proteins in cells and tissue samples.
Ticker
$MRVI
Sector
Primary listing
Employees
560
Headquarters
Website
MRVI Metrics
BasicAdvanced
$503M
-
-$1.35
0.28
-
Price and volume
Market cap
$503M
Beta
0.28
52-week high
$7.76
52-week low
$1.67
Average daily volume
1.6M
Financial strength
Current ratio
5.163
Quick ratio
4.274
Long term debt to equity
76.25
Total debt to equity
79.293
Interest coverage (TTM)
-2.87%
Profitability
EBITDA (TTM)
-60.204
Gross margin (TTM)
30.53%
Net profit margin (TTM)
-87.57%
Operating margin (TTM)
-50.21%
Effective tax rate (TTM)
1.11%
Revenue per employee (TTM)
$390,000
Management effectiveness
Return on assets (TTM)
-5.89%
Return on equity (TTM)
-54.84%
Valuation
Price to revenue (TTM)
2.26
Price to book
1.89
Price to tangible book (TTM)
-8.89
Price to free cash flow (TTM)
-10.991
Free cash flow yield (TTM)
-9.10%
Free cash flow per share (TTM)
-0.317
Growth
Revenue change (TTM)
-19.95%
Earnings per share change (TTM)
33.60%
3-year revenue growth (CAGR)
-37.95%
3-year earnings per share growth (CAGR)
-10.95%
What the Analysts think about MRVI
Analyst ratings (Buy, Hold, Sell) for Maravai LifeSciences stock.
Bulls say / Bears say
Q1 2025 revenue reached $46.9 million, beating guidance. Base business revenue, excluding high-volume CleanCap orders, grew by more than $4 million sequentially—demonstrating solid operational execution under tough market conditions. (GlobeNewswire)
TriLink BioTechnologies signed a Memorandum of Understanding with the International Vaccine Institute to work together on mRNA vaccine research and development, with the goal of expanding vaccine access in low- and middle-income countries. This move broadens Maravai’s reach in a fast-growing market segment. (Business Wire)
Maravai’s TriLink unit signed a non-exclusive License and Supply Agreement with Quantoom Biosciences to incorporate CleanCap® mRNA capping technology into Quantoom’s Ntensify® manufacturing platform. This shows industry leadership with over 95 percent capping efficiency and strengthens CDMO partnerships. (Nasdaq via Business Wire)
Nucleic Acid Production revenue fell 43.1 percent year-over-year to $31.1 million in Q2 2025, revealing a sharp drop in high-volume CleanCap orders and highlighting Maravai’s exposure to post-pandemic demand shifts. (GlobeNewswire)
The company posted a net loss of $69.8 million in Q2 2025, including a $30.4 million goodwill impairment, increasing pressure on profitability and raising concerns about the sustainability of its current cost structure. (GlobeNewswire)
Maravai is the subject of a securities class action lawsuit over a $3.9 million revenue misstatement and has acknowledged material weaknesses in its internal controls, hurting its credibility and investor confidence. (Hagens Berman)
Data summarised monthly by Lightyear AI. Last updated on 15 Oct 2025.
MRVI Financial Performance
Revenues and expenses
MRVI Earnings Performance
Company profitability
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Maravai LifeSciences stock?
Maravai LifeSciences (MRVI) has a market cap of $503M as of October 24, 2025.
What is the P/E ratio for Maravai LifeSciences stock?
The price to earnings (P/E) ratio for Maravai LifeSciences (MRVI) stock is 0 as of October 24, 2025.
Does Maravai LifeSciences stock pay dividends?
No, Maravai LifeSciences (MRVI) stock does not pay dividends to its shareholders as of October 24, 2025.
When is the next Maravai LifeSciences dividend payment date?
Maravai LifeSciences (MRVI) stock does not pay dividends to its shareholders.
What is the beta indicator for Maravai LifeSciences?
Maravai LifeSciences (MRVI) has a beta rating of 0.28. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.